Answers are grounded in this paper and cite their sources.
Two articles in this issue of the Journal tell a similar story: primary acute myeloid leukemia (AML) may be divided into subclasses according to gene-expression profiles. Given the number of articles that describe the correlative and predictive usefulness of array-based molecular classifications, especially in leukemias, these outcomes no longer elicit surprise. But perhaps they should — not only because of their clinical usefulness, as outlined in the editorial by Grimwade and Haferlach (pages 1676–1678), but also because of the rapid pace at which expression genomics is changing the conduct of clinical research.Not too long ago, a single molecular marker, . . .
No takes yet. Share an insight, caveat, or question.
Liu et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: